Categories AlphaGraphs, Earnings, Finance, LATEST
BlackRock earnings fall short of estimates in the fourth quarter
BlackRock, Inc. (BLK) on Wednesday reported underwhelming financial results for the three months ended December 31, 2018, before the market opened for regular trade.
Net income slumped 60% to $927 million or $5.78 per diluted share, on a revenue slide of 9% to $3.43 billion.
Analysts had expected $6.35 per share earnings on revenue of $3.61 billion. Both top line and bottom line failed to beat the consensus.
Assets Under Management (AUM) for BlackRock slipped 5% in the quarter, while operating income slumped 16% to $1.25 billion.
“BlackRock generated total net inflows of $124 billion in 2018. This included $50 billion of fourth quarter net inflows and record quarters for iShares and illiquid alternative strategies. Technology services revenue grew 19% in 2018, driven by strong demand for Aladdin and our digital wealth technologies,” said BlackRock CEO Laurence D. Fink.
DIVIDEND HIKED
BlackRock announced that its board approved a 5% rise in the quarterly cash dividend to $3.30 per share, payable March 21, 2019, to shareholders of record at the close of business on March 6, 2019.
FALL IN REVENUES
BlackRock reported that its advisory, administration fees and securities lending revenue fell $118million in the fourth quarter from a year ago. This trend continued from the third quarter when it lost $104 million.
BlackRock has failed to capitalize on the positive organic growth and AUM acquired from its TCP and Citibanamex transactions. This looks like the impact of lower markets, pricing changes to select investment products and lower borrowing demand for securities lending in the current environment.
Securities lending revenue was just $129 million in the current quarter, vs. $150 million in the fourth quarter of 2017.
We’re on Flipboard! Follow us to receive the latest stock market, earnings, and financial news at your fingertips
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on